Literature DB >> 10699313

Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cells. mangala.rao@na.amedd.army.mil.

M Rao1, C R Alving.   

Abstract

Liposomes have the well-known ability to channel protein and peptide antigens into the MHC class II pathway of phagocytic antigen-presenting cells (APCs) and thereby enhance the induction of antibodies and antigen-specific T cell proliferative responses. Liposomes also serve as an efficient delivery system for entry of exogenous protein and peptide antigens into the MHC class I pathway and thus are very efficient inducers of cytotoxic T cell responses. Soluble antigens that are rendered particulate by encapsulation in liposomes are localized both in vacuoles and in the cytoplasm of bone marrow-derived macrophages. Utilizing fluorophore-labeled proteins encapsulated in liposomes we have addressed the question of how liposomal antigens enter the MHC class I pathway. After phagocytosis of the liposomes, the fluorescent liposomal protein and liposomal lipids enter the cytoplasm where they are processed by the proteasome complex. The processed liposomal protein is then transported via the TAP complex into the endoplasmic reticulum and the Golgi complex. Both the liposomal lipids and the liposomal proteins appear to follow the same intracellular route and they are processed as a protein-lipid unit. In the absence of a protein antigen (empty liposomes), there is no organelle-specific localization of the liposomal lipids. In contrast, when a protein is encapsulated in these liposomes, the distribution of the liposomal lipids is dramatically affected and the liposomal lipids localize to the trans-Golgi area. Localization of the protein in the trans-Golgi area requires liposomal lipids. Similarly, for the localization of liposomal lipids in the trans-Golgi area, there is an obligatory requirement for protein. Therefore, the intracellular trafficking patterns of liposomal lipids and liposomal protein are reciprocally regulated. Presence of both liposomal lipids and liposomal protein in the trans-Golgi therefore facilitates the entry of liposomal antigens into the MHC class I pathway. It is also possible that liposomal lipids are presented to T cells via the recently described CD1 pathway for lipid antigens. Because liposome-formulated vaccines have the potential to stimulate antibody as well as cellular immune responses to protein and lipid components, this approach could prove to be extremely useful in designing vaccine strategies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10699313     DOI: 10.1016/s0169-409x(99)00064-2

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  18 in total

Review 1.  Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens.

Authors:  Douglas S Watson; Aaron N Endsley; Leaf Huang
Journal:  Vaccine       Date:  2012-02-02       Impact factor: 3.641

Review 2.  Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials.

Authors:  Hyun Jun Park; Sattva S Neelapu
Journal:  Br J Haematol       Date:  2008-04-13       Impact factor: 6.998

Review 3.  Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor.

Authors:  Yinghuan Li; Jie Wang; M Guillaume Wientjes; Jessie L-S Au
Journal:  Adv Drug Deliv Rev       Date:  2011-05-03       Impact factor: 15.470

Review 4.  Liposomal adjuvant development for leishmaniasis vaccines.

Authors:  Anis Askarizadeh; Mahmoud Reza Jaafari; Ali Khamesipour; Ali Badiee
Journal:  Ther Adv Vaccines       Date:  2017-11-15

5.  Pretreatment with empty liposomes attenuates the immunopathology of invasive pulmonary aspergillosis in corticosteroid-immunosuppressed mice.

Authors:  Russell E Lewis; Georgios Chamilos; Randall A Prince; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2006-12-28       Impact factor: 5.191

6.  Comparison of BCG, MPL and cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral leishmaniasis.

Authors:  Rajesh Ravindran; Sudipta Bhowmick; Amrita Das; Nahid Ali
Journal:  BMC Microbiol       Date:  2010-06-24       Impact factor: 3.605

Review 7.  Development of multifunctional nanoparticles for targeted drug delivery and noninvasive imaging of therapeutic effect.

Authors:  Hari Krishna Sajja; Michael P East; Hui Mao; Y Andrew Wang; Shuming Nie; Lily Yang
Journal:  Curr Drug Discov Technol       Date:  2009-03

8.  Mucosal adjuvanticity of a Shigella invasin complex with dna-based vaccines.

Authors:  Robert W Kaminski; K Ross Turbyfill; C Chao; W M Ching; Edwin V Oaks
Journal:  Clin Vaccine Immunol       Date:  2009-02-18

9.  gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani.

Authors:  Swati Bhowmick; Rajesh Ravindran; Nahid Ali
Journal:  Infect Immun       Date:  2008-01-14       Impact factor: 3.441

Review 10.  Army Liposome Formulation (ALF) family of vaccine adjuvants.

Authors:  Carl R Alving; Kristina K Peachman; Gary R Matyas; Mangala Rao; Zoltan Beck
Journal:  Expert Rev Vaccines       Date:  2020-03-31       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.